Literature DB >> 6299799

The presence of LHRH-like receptors in Dunning R3327H prostate tumors.

M T Hierowski, P Altamirano, T W Redding, A V Schally.   

Abstract

Quantitative analyses of LH-RH-like membrane receptors were performed in five tumors from the transplantable Dunning R3372H rat prostatic adenocarcinoma. The binding of D-Trp6-LH-RH, an agonist of LH-RH, was observed in all 5 tumors. The antagonist [Ac-Dp-Cl-Phe1,2,D-Trp3,D-Lys6, D-Ala10]-LH-RH was bound to 4 tumors. The apparent equilibrium dissociation constant (Kd) for D-Trp6-LH-RH receptor was from 2.6-3.9 x 10(-10) M. The apparent equilibrium Bmax values (maximum number of binding sites) were from 17.2-86.0 fmol/mg membrane protein for D-Trp6-LH-RH receptor. The Kd for the antagonist was from 2.4-2.7 x 10(-10) M and the Bmax values were from 35.5-66.0 fmol/mg membrane protein. Similar binding studies performed in 6 normal rat prostates showed no binding capacities.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6299799     DOI: 10.1016/0014-5793(83)80881-3

Source DB:  PubMed          Journal:  FEBS Lett        ISSN: 0014-5793            Impact factor:   4.124


  5 in total

1.  The effect of gastrointestinal hormones on the incorporation of tritiated thymidine in the pancreatic adenocarcinoma cell line (WD PaCa).

Authors:  B F Edwards; T W Redding; A V Schally
Journal:  Int J Pancreatol       Date:  1989-09

Review 2.  Luteinizing hormone-releasing hormone and its analogues: a review of biological properties and clinical uses.

Authors:  B J Furr; J R Woodburn
Journal:  J Endocrinol Invest       Date:  1988 Jul-Aug       Impact factor: 4.256

3.  Inhibition of the growth of some hormone dependent tumors by D-Trp6-LH-RH.

Authors:  A V Schally; T W Redding; A M Comaru-Schally
Journal:  Med Oncol Tumor Pharmacother       Date:  1984

4.  Receptors for prolactin, somatostatin, and luteinizing hormone-releasing hormone in experimental prostate cancer after treatment with analogs of luteinizing hormone-releasing hormone and somatostatin.

Authors:  T Kadar; T W Redding; M Ben-David; A V Schally
Journal:  Proc Natl Acad Sci U S A       Date:  1988-02       Impact factor: 11.205

5.  Inhibition of growth of experimental prostate cancer with sustained delivery systems (microcapsules and microgranules) of the luteinizing hormone-releasing hormone antagonist SB-75.

Authors:  E Korkut; L Bokser; A M Comaru-Schally; K Groot; A V Schally
Journal:  Proc Natl Acad Sci U S A       Date:  1991-02-01       Impact factor: 11.205

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.